BUZ Routes, Frequency + Reliability - the winning formula

Institute of Transport and Logistics Studies. Faculty of Economics and Business. The University of Sydne

Editors' introduction to special theme issue [of International Journal of Pedagogies and Learning]: Meanings emerging in practice (Part 3)

This issue publishes the third and final set of refereed papers from the first wave proceedings of the 3rd International Conference on Pedagogies and Learning, held at the Springfield Campus of the University of Southern Queensland in Australia on 27 and 28 September 2007. This third conference in the series focused on “Meanings Emerging in Practice” as a lens for examining and evaluating multiple enactments of pedagogies and learning

Centre Line Removal or non-reinstatement

In 2018 researchers from the University of the West of England undertook a study which asked the question: What is the impact of Centre Line Removal (CLR) or non-re-instatement on 20mph and 30mph speed limit roads as a contributor to cycle safety? Cycle user perceptions of road danger are significantly a function of driver speed. The sense of danger is substantially increased when speeds driven are above posted 20 and 30mph limits on unsegregated roads. Achieving driver speed limit compliance is, however, very difficult without traffic calming or enforcement. In terms of 20mph speed limits, while there is consistent majority public support in Great Britain (Department for Transport 2012; Tapp et al 2015), driver compliance is more problematic. Moreover, previous UK research has reported that overtaking speeds on 20 and 30mph roads were reduced if there was no centre-line present (Shackel, Parkin, 2014). The literature is not clear as to the causation of lower speeds without centre lines but it may be that cognitive load increases without the certainty of a centre-line so drivers slow in order to gain more time to respond (Murphy, Greene, 2017). Road types are typically village roads and local distributor roads in urban areas which are single carriageway two-way with opposing flows with the centre-line removed or not reinstated

A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis

International audienceThis paper presents numerical crack propagations in case of explicit dynamics, and applied to eXtended Finite Element Method. The interest of this method is non remeshing. Hence the crack propagates through the constant mesh. Only some elements cut by the crack can have critical time step close to zero. To avoid this case, the lumping technique of mass matrix will allow to obtain the same critical time step than the case without crack: a crack and its propagation do not modify the critical time step of the whole structure. To conclude, we have $\Delta t_\text{c}^\text{X-FEM} = \Delta t_\text{c}^\text{FEM}$ for some elements.Ce papier traite de la simulation numérique de propagation dynamique de fissure dans le cas particulier de calcul explicite, et appliquée à la méthode des éléments finis étendus. L'intérêt de cette méthode est le non-remaillage. Effectivement, la fissure se propage dans le maillage invariant. Seulement certains éléments, coupés par la fissure, peuvent avoir des pas de temps critiques de calcul presque nuls. Pour s'affranchir de ces cas pénalisant le calcul, la méthode de diagonalisation de matrice de masse va permettre d'obtenir le même pas de temps critique que le cas sans fissure : l'introduction d'une fissure et sa propagation ne modifie pas le pas de temps critique de la structure. Au final, on a dans certains cas $\Delta t_\text{c}^\text{X-FEM} = \Delta t_\text{c}^\text{FEM}$

Emerging Therapies for the Treatment of Psoriasis

Psoriasis is an immune-mediated disease that affects 1%–2% of the European and North American population. While topical agents such as corticosteroids and vitamin D derivatives are prescribed for mild disease, they are generally unable to adequately control patients with more severe disease. Over the past decade, research into the immunopathogenesis of psoriasis, including investigations into the role of tumor necrosis factor-alpha and more recently interleukins (IL) 12/23, has led to the advent of targeted biologic therapies based on the central role of a new subset of T cells, Th17. Because of their increased specificity, biologic agents have revolutionized short- to medium-term treatment outcomes and safety profiles for moderate to severe disease over previously gold standard systemic agents. The immunopathogenesis of the disease is still a focus for researchers and novel targets for future agents are being discovered and investigated in clinical trials. In particular, specifically targeting the IL-23/Th17 pathway has given rise to IL-23p19 and IL-17 antagonists, both of which have shown significant promise in clinical trials. IL-22 is involved in keratinocyte proliferation and is being studied as a treatment target for psoriasis. New small molecule oral agents, including Janus kinase and phosphodiesterase inhibitors are currently in phase 2 and 3 clinical trials